ASCO: Time Management for the Busy Oncologist

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Tim Moynihan of the Mayo Clinic in Minnesota discusses topics from the session he chaired at ASCO, "Effective Time Management for the Busy Oncologist," including why EHRs may not actually save physicians time; how to manage your email load; and tips for avoiding burnout, which he cites as a danger in such a physically and emotionally taxing profession.

Tim Moynihan of the Mayo Clinic in Minnesota discusses topics from the session he chaired at ASCO, "Effective Time Management for the Busy Oncologist," including why EHRs may not actually save physicians time; how to manage your email load; and tips for avoiding burnout, which he cites as a danger in such a physically and emotionally taxing profession.

Recent Videos
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Related Content
Data from a phase 1b/2 trial show that sonrotoclax/dexamethasone appears to be well tolerated in a heavily pretreated multiple myeloma population.

Novel BCL-2 Inhibitor Combo Shows Enduring Responses in R/R Myeloma Subtype

Ryan Scott
October 5th 2024
Article

Data from a phase 1b/2 trial show that sonrotoclax/dexamethasone appears to be well tolerated in a heavily pretreated multiple myeloma population.

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Exploring New Possibilities in Kidney Cancer Detection and Therapy

Karl Semaan, MD, MSc ;Neil J. Shah, MBBS;Bradley McGregor, MD
July 22nd 2024
Podcast

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Nearly all patients in the per-protocol population of the MIDAS study achieved a very good partial response or better following study treatment.

Isatuximab Combo Yields MRD-Negative Responses in Transplant-Eligible NDMM

Jordyn Sava
October 4th 2024
Article

Nearly all patients in the per-protocol population of the MIDAS study achieved a very good partial response or better following study treatment.

Experts discuss updated findings presented at the 2024 EHA Congress in diseases such as mantle cell lymphoma and acute myeloid leukemia.

Ensuring Quality Outcomes in Hematologic Cancer Subgroups at EHA 2024

Manali Kamdar, MD;Michael Grunwald, MD;Harry P. Erba, MD, PhD
June 24th 2024
Podcast

Experts discuss updated findings presented at the 2024 EHA Congress in diseases such as mantle cell lymphoma and acute myeloid leukemia.

Results from the INNATE trial showed the use of sotigalimab to be a safe and efficacious regimen for patients with rectal cancer.

Neoadjuvant Sotigalimab Proves Efficacious in Rectal Cancer

Ariana Pelosci
October 3rd 2024
Article

Results from the INNATE trial showed the use of sotigalimab to be a safe and efficacious regimen for patients with rectal cancer.

Data show that twice-daily radiotherapy may confer improved survival vs once-daily radiation in patients with limited-stage small cell lung cancer.

Concurrent Chemoradiation/Atezolizumab Does Not Improve Survival in LS-SCLC

Russ Conroy
October 3rd 2024
Article

Data show that twice-daily radiotherapy may confer improved survival vs once-daily radiation in patients with limited-stage small cell lung cancer.